Across progression trajectories, our results show that expression of genes related to ADP‐ribosylation decreased as tumors progressed (while PARP1 and PARP2 increased or remained stable), suggesting the potential for a differential response to PARP inhibitors based on cancer progression. This evidence concerns the gene PARP1 and cancer.